Table 2 Comparison of Clostridioides difficile infection patient characteristics in the treatment success and failure groups after the vancomycin tapered and pulsed-dose regimen
Treatment success (n = 23) | Treatment failure (n = 13) | p value | |
|---|---|---|---|
Male sex (%) | 12 (52.2) | 7 (53.8) | 0.5492 |
Age, median (IQR1) | 80 (73–83.5) | 83 (76–87) | 0.2813 |
No. of CDI episodes, mode (range) | 3 (2–7) | 3 (2–7) | 0.1153 |
Underlying disease | |||
Hypertension (%) | 8 (34.8) | 4 (30.8) | 1.0002 |
Malignancy (%) | 7 (30.4) | 3 (23.1) | 0.7162 |
Immunocompromised (%) | 5 (21.7) | 4 (30.8) | 0.6932 |
Diabetes mellitus (%) | 4 (17.4) | 1 (7.7) | 0.6342 |
Prior abdominal surgery (%) | 3 (13.0) | 2 (15.4) | 1.0002 |
Chronic kidney disease (%) | 3 (13.0) | 1 (7.7) | 1.0002 |
Chronic liver disease (%) | 1 (4.3) | 0 (0) | 1.0002 |
Charlson comorbidity index, median (range) | 2 (0–8) | 2 (0–5) | – |
Drug use | |||
Proton pump inhibitors (%) | 10 (43.5) | 6 (46.2) | 0.8774 |
Histamine receptor-2 blockers (%) | 3 (8.3) | 0 (0.0) | 0.2882 |
Probiotics (%) | 19 (82.6) | 12 (92.3) | 0.6342 |
Antidiarrheals (%) | 0 (0.0) | 0 (0.0) | – |
Antibiotic use prior 90 days (%) | 21 (91.3) | 12 (92.3) | 1.0002 |
Penicillins | 7 | 1 | |
Cephalosporins | 6 | 4 | |
Carbapenems | 6 | 3 | |
Quinolones | 5 | 3 | |
Antitubercular | 6 | 5 | |
Others | 4 | 3 | |
Concomitant antibiotics during VCM-TP5 (%) | 16 (69.6) | 6 (46.2) | 0.5492 |
Disease severity (%) | |||
Zar criteria [14] | 0.1664 | ||
> 2 | 2 (8.7) | 3 (23.1) | |
≤ 2 | 21 (91.3) | 10 (76.9) | |
MN criteria [15] | 0.3734 | ||
mild | 6 (16.7) | 7 (53.8) | |
moderate | 14 (60.9) | 5 (38.5) | |
severe | 2 (8.7) | 1 (7.7) | |
Recommended VCM-TP6 (%) | 22 (95.7) | 8 (61.5) | 0.0162 |